Alector opened lower at $2.20, compared with its previous close of $2.24. In the last trading session, the stock traded between $2.09 and $2.25. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Alector is now worth
$ 9.87
resulting in a loss of
$ 90.13 (90.13%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 7 Analysts
Buy
28.57%
Hold
42.86%
Sell
28.57%
Markets Today
Today's Change
$-0.10 (-4.24%)
Day High
$2.25
Day Low
$2.09
Day Open
$2.20
Prev Close
$2.24
Volume
4,14,588
1W Return
17.34%
1M Return
14.22%
3M Return
41.58%
6M Return
-6.74%
1Y Return
38.39%
Fundamentals
Market Cap ($ Mn)
318
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-187.60%
ROCE
-51.25%
EPS (TTM)
$-0.21
Investment Returns
1 Week
17.34%
1 Month
14.22%
3 Months
41.58%
6 Months
-6.74%
9 Months
12.30%
Financials
Quarterly
All values in $ Mn
3.7
Mar 25
7.9
Jun 25
3.3
Sep 25
6.2
Dec 25
1.0
Mar 26
3.3
Jun 26
Updates
16Oct
Alector prices $75 million underwritten offering at $2.05 per share
Alector Inc. priced an underwritten offering of 36,600,000 shares at $2.05 per share. Gross proceeds expected to reach $75,030,000.00 before deducting expenses. Offering price represents a 7.3% premium over the October 15, 2026 closing price. Net proceeds will fund research, development, manufacturing, and general corporate purposes.
14 days ago
14Oct
HC Wainwright raises Alector price target to $8, maintains Buy
HC Wainwright & Co. maintains a Buy rating on Alector. Price target raised from $5 to $8 by analyst Andrew S. Fein. New target represents a $3 increase over the previous estimate.
16 days ago
8Oct
Alector schedules virtual R&D event on ABC-enabled pipeline
Alector Inc. will host a virtual R&D event on October 13, 2026, at 8:00 am PT. Agenda covers progress on AL137, AL164, and AL062 programs using the ABC platform. AL137 targets pyroglutamate Aβ with monthly subcutaneous dosing. siRNA programs AL164, AL062, and ADP065 aim for once-quarterly subcutaneous dosing.
22 days ago
5Oct
Alector signs $1.27 billion global licensing deal with Genentech
Alector receives $100 million upfront from Genentech for AL050 licensing. Deal includes up to $1.17 billion in potential milestone payments. Total potential value of the agreement is $1.27 billion. Cash runway extended into 2029 to support broader pipeline advancement.
